Clinical trial NCT01465100: Liver Cell Transplant for Phenylketonuria
Official title: Hepatocyte Transplantation for Phenylketonuria
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Phenylketonuria
Keywords: phenylketonuria
hepatocyte
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2011-11-04
Enrollment: 1
Sex: ALL
Minimum age (years): 14
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Human phenylketonuria (PKU) results from phenylalanine hydroxylase (PAH) deficiency, and represents one of the most common and extensively studied single-gene Mendelian disorders in humans. Unfortunately, optimum clinical outcome demands lifelong dietary restriction through adherence to an unpalatable and expensive artificial diet. Challenges in maintaining traditional therapy lead to increasing phenylalanine (Phe) levels in patients as they approach adulthood with an incumbent severe burden of psychosocial and intellectual difficulties. The recent introduction of the new medication Sapropterin for treatment of PKU has improved Phe control and dietary tolerance in some patients, but at enormous cost to patients and insurers for the FDA designated orphan product. Thus, there is an unmet need for novel therapies to correct PKU. PAH is almost exclusively expressed in the liver in humans. The main objective of the current proposal is to examine the safety and efficacy of hepatocyte transplantation in patients with PKU.

Detailed description: Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process. We have previously estimated that the hepatic mass of a recipient approaches 4 x 10 to the 9th power hepatocytes/kg. However, this is just an estimate and the true mass may be twice this number. Our goal is to attempt to infuse at least 2x10 to the 8th power cells/kg. Once it has been determined that IND release criteria for the hepatocytes has been met, the patient will then receive Intensity-Modulated Radiation Therapy (IMRT), and the hepatocyte transplant will begin.

Preparative Liver Irradiation: A portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT). Respiratory gating will be used to further increase the accuracy of delivering the dose to a specified volume and limiting the exposure to adjacent tissues. After hepatic irradiation, the right or main portal vein will be occluded transiently (0-90 min) to provide a compensatory mitotic signal to donor hepatocytes. Transient portal vein occlusion or embolization has been shown in primates to provide the appropriate mitotic signals necessary for donor cell proliferation. At that time, donor hepatocytes will be transplanted into the irradiated portion of the recipient's liver.

The number of infusions from each donor liver will depend on the tolerance of the patient to infusion (avoidance of portal vein thrombosis and portal vein to systemic venous system shunting), and viability of donor hepatocytes. The hepatocytes from each donor liver will be given over three to four infusions, every 6 to 8 hours, until the cells are no longer viable, approximately twenty-four hours after initial preparation. Ideally, the infusion catheter will be maintained just outside the portal circulation in the umbilical vein remnant so the patient can be potentially discharged from the hospital until the next donor liver is available. Since we do not yet know from our experience the number of cells needed for transplant in order to improve function so that a metabolic disease is cured, we will continue to infuse hepatocytes as donors become available until reaching the goal volume of hepatocytes and until viability of cells has expired. Using hepatocytes from multiple donors will help to ensure that an adequate number of cells is infused while maintaining portal pressure in the normal range.Phe levels will be collected once a week by the subject, using a capillary blood sample on a newborn screening filter paper, and mailed to CHP. Phe levels will also be collected in a venous sample monthly. During months when a Follow-Up Visit is scheduled, both a venous and capillary sample will be collected.

Subjects will receive careful dietary observation post-transplant through the UPMC Children's Hospital of Pittsburgh Division of Medical Genetics research dietician. Three-day diet records will be completed once a month for six months, then every three months thereafter. Diet should remain unchanged throughout the study, unless directed by study staff.

Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.

Isotopic monitoring of whole body Phe oxidation will be performed at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.

Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.

Eligibility criteria: Inclusion Criteria:

1. Previous diagnosis of classical PKU, as determined by a PAH mutation known to cause classical PKU, or a Phe \>20 mg/dL at any time.
2. Patients must have poor control on standard therapy (i.e. Kuvan or diet alone) as defined by two consecutive Phe levels of \> 12 mg/dL in the past six months. This is two times the recommended level. If the patient is being treated with Palynziq, they must discontinue treatment for at least two months before participating in this trial.
3. Baseline I.Q. ≥70 as assessed by Wechsler Abbreviated Scale of Intelligence (4-subtest IQ)
4. Must have a complete evaluation, including dietary records, in a PKU clinic in the past twelve months
5. Age between 14 and 55 years
6. Stated willingness to comply with all study procedures and availability for the duration of the study
7. Sexually active female subjects must agree to use two highly effective forms of contraception for the duration of the study

Exclusion Criteria:

1. I.Q. \<70
2. Known biopterin synthesis defects
3. Subject has active malignancy
4. Subject has known allergy or other contraindication to immune suppression medications (and their alternatives) required post transplant for the prevention of rejection
5. Subject has sepsis, pneumonia, other active infection, or other secondary life-threatening organ dysfunction at Screening or Baseline Visits. Subject may be re-screened once infection has cleared.
6. Subject is pregnant or breastfeeding
7. Subject has positive HIV serostatus
8. Liver biopsy shows significant fibrosis, defined by the Ishak Stage 5: bridges with occasional nodules, or higher. Liver biopsy will be performed if, in the clinical judgment of the investigators, subject has clinical signs of liver failure, or increased risk of liver fibrosis.
9. Any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or not completing the required study follow-up
10. Concurrent disease or condition that would interfere with study participation or safety

Primary outcomes:
measure: Improvement/reversal of characteristics of PKU
timeFrame: 24 months post hepatocyte transplant
Secondary outcomes:
measure: Engraftment of Hepatocytes
timeFrame: 3 months
measure: Engraftment of Hepatocytes
timeFrame: 12 months
measure: Engraftment of Hepatocytes
timeFrame: up to 24 months
measure: Wechsler Abbreviated Scale of Intelligence-third edition (WASI-III)
timeFrame: 6 months
measure: Wechsler Abbreviated Scale of Intelligence-third edition (WASI-III)
timeFrame: 12 months
measure: Wechsler Abbreviated Scale of Intelligence-third edition (WASI-III)
timeFrame: 24 months
measure: Delis Kaplan Executive Functioning System (D-KEFS)
timeFrame: 6 months
measure: Delis Kaplan Executive Functioning System (D-KEFS)
timeFrame: 12 months
measure: Delis Kaplan Executive Functioning System (D-KEFS)
timeFrame: 24 months
measure: Connors Continuous Performance Test-third edition (CPT-III)
timeFrame: 6 months
measure: Connors Continuous Performance Test-third edition (CPT-III)
timeFrame: 12 months
measure: Connors Continuous Performance Test-third edition (CPT-III)
timeFrame: 24 months
measure: Adaptive Behavior Assessment System-third edition (ABAS-III)
timeFrame: 6 months
measure: Adaptive Behavior Assessment System-third edition (ABAS-III)
timeFrame: 12 months
measure: Adaptive Behavior Assessment System-third edition (ABAS-III)
timeFrame: 24 months
measure: SF-36 Health Survey
timeFrame: 6 months
measure: SF-36 Health Survey
timeFrame: 12 months
measure: SF-36 Health Survey
timeFrame: 24 months
measure: Beck Depression Inventory
timeFrame: 6 months
measure: Beck Depression Inventory
timeFrame: 12 months
measure: Beck Depression Inventory
timeFrame: 24 months
measure: Behavior Rating Inventory of Executive Function (BRIEF-parent version)
timeFrame: 6 months
measure: Behavior Rating Inventory of Executive Function (BRIEF-parent version)
timeFrame: 12 months
measure: Behavior Rating Inventory of Executive Function (BRIEF-parent version)
timeFrame: 24 months
measure: Behavior Assessment System for Children-second edition (BASC-II)
timeFrame: 6 months
measure: Behavior Assessment System for Children-second edition (BASC-II)
timeFrame: 12 months
measure: Behavior Assessment System for Children-second edition (BASC-II)
timeFrame: 24 months
measure: Child Health Questionnaire (CHQ)
timeFrame: 6 months
measure: Child Health Questionnaire (CHQ)
timeFrame: 12 months
measure: Child Health Questionnaire (CHQ)
timeFrame: 24 months
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: UPMC Children's Hospital of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Ira J Fox, MD
role: PRINCIPAL_INVESTIGATOR
References: